Customize this page|
0
Votes
vote
FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanomaEnzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma. ... |
|
2
Votes
vote
Scientists report new development for diagnosing malignant melanomaScientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer. Their study is scheduled for the September 10 issue of the ACS' Journal of the Medicinal Chemistry, a bi-weekly ... |
|
2
Votes
vote
Melanoma on the Rise, or Is It Just Diagnoses?A study found evidence that an epidemic of malignant melanoma might be due in part to a growing tendency to identify and treat benign lesions as malignant cancers. ... |
|
3
Votes
vote
CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanomaOncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in ... |
|
2
Votes
vote
New drug 'hits melanoma's Achilles heel'Scientists say a breakthrough drug for treating the deadliest form of skin cancer could be on shelves within a couple of years. ... |
|
2
Votes
vote
Trial of new treatment for advanced melanoma shows rapid shrinking of tumorsBerlin, Germany: Researchers have made significant advances in the treatment of metastatic malignant melanoma -- one of the most difficult cancers to treat successfully once it has started to spread -- according to a study to be presented at Europe's largest cancer congress, ECCO 15 -- ESMO 34... |
